Please login to the form below

Not currently logged in
Email:
Password:

ESMO 2012

This page shows the latest ESMO 2012 news and features for those working in and with pharma, biotech and healthcare.

Roche's T-DM1 activity in breast cancer "outstanding"

Roche's T-DM1 activity in breast cancer

The new data from the EMILIA study were presented yesterday at the European Society for Medical Oncology (ESMO) annual meeting, and come from a study involving patients with HER2-positive breast ... 2nd October 2012.

Latest news

  • Ariad’s lung cancer drug impresses at ESMO

    Ariad’ s lung cancer drug impresses at ESMO. Early stage trials demonstrate potential in hard-to-treat patients. ... Presenting data at the annual congress of the European Society for Medical Oncology (ESMO 20120) in Vienna, Austria, Ariad said that an

  • Merck withdraws EU filing for Erbitux in lung cancer Merck withdraws EU filing for Erbitux in lung cancer

    Merck already sells Erbitux as a treatment for metastatic colorectal cancer and squamous cell carcinoma of the head and neck, bringing in 430m in the first six months of 2012, but ... The data will be presented at the European Society for Medical

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics